Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:08:04.287Z.
Calculation as of: 2026-10-06T16:08:04.287Z.
Quote observation: 2026-10-06T16:05:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e4c5e5530b5f4ff9b2ae64c4564a307684e7c74323ce66c5db527ab157f5d0a0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
IceCure Medical Ltd
Market Cap
$3.18M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| IceCure Medical Ltd (ICCM) | $3.18M | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.07M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.17M | N/A |
| Revelation Biosciences, Inc. (REVB)vs › | $3.04M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.00M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.29M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.38M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.39M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.41M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
